Vimarsana
Biggest News Aggregation in the World

Page 32 - Topline News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Topline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Topline Today - Breaking & Trending Today

Seagen Inc.: Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer - Vimarsana News

Seagen Inc.: Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

- Data Accepted for Presentation at ESMO World Congress on Gastrointestinal Cancer - Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical

AbbVie Announces Positive Topline Results From U-ENDURE Phase 3 Study Evaluating Upadacitinib - Vimarsana News

AbbVie Announces Positive Topline Results From U-ENDURE Phase 3 Study Evaluating Upadacitinib

WASHINGTON (dpa-AFX) - Biopharmaceutical company AbbVie Inc. (ABBV) announced on Wednesday positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult

Related Topics:
United StatesAbbvie Inc
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update - Vimarsana News

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

Cystic Fibrosis Foundation  awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis Phase 2 expansion... | May 10, 2022

Horizon Therapeutics plc: Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis - Vimarsana News

Horizon Therapeutics plc: Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis

Detailed results to be presented at upcoming medical congress Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep

Genmab A/S: Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) - Vimarsana News

Genmab A/S: Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Company Announcement Based on the topline results from the EPCORE NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical